161 related articles for article (PubMed ID: 37905611)
1. Socioeconomic Impact of OncotypeDX on Breast Cancer Treatment: Preliminary Results.
Vanni G; Materazzo M; Portarena I; Pellicciaro M; Meacci A; Pizzimenti AR; Buonomo OC
In Vivo; 2023; 37(6):2510-2516. PubMed ID: 37905611
[TBL] [Abstract][Full Text] [Related]
2. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
3. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
4. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
5. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
7. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
8. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
[TBL] [Abstract][Full Text] [Related]
9. Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study.
Barni S; Cognetti F; Petrelli F
Breast Cancer Res Treat; 2022 Jan; 191(2):477-480. PubMed ID: 34817748
[TBL] [Abstract][Full Text] [Related]
10. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
[TBL] [Abstract][Full Text] [Related]
11. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
McVeigh TP; Hughes LM; Miller N; Sheehan M; Keane M; Sweeney KJ; Kerin MJ
Eur J Cancer; 2014 Nov; 50(16):2763-70. PubMed ID: 25240289
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
14. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
15. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
16. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.
Choi JDW; Hughes TMD; Marx G; Boyages J; Rutovitz J; Hasovits C; Parasyn A; Edirimanne S; Ngui NK
Breast J; 2022; 2022():1199245. PubMed ID: 35711899
[TBL] [Abstract][Full Text] [Related]
17. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
18. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
19. Results of PONDx, a prospective multicenter study of the Oncotype DX
Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
[TBL] [Abstract][Full Text] [Related]
20. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
